|
CAMBRIDGE, MA — July 21, 2005
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the pricing
of a public offering of 4,827,300 shares of its common stock at $27.02
per share. All of the shares are being offered by Momenta pursuant to
its effective shelf registration statement previously filed with the
Securities and Exchange Commission. Momenta has granted an option to
the underwriters to purchase up to 724,095 additional shares of common
stock within 30 days of the offering to cover over-allotments, if any.
Morgan Stanley & Co. Incorporated acted as the
sole book runner for this offering. Deutsche Bank Securities Inc. acted
as co-lead manager of the offering. Co-managers for the offering were
Banc of America Securities LLC and SG Cowen & Co., LLC.
This communication shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be any
sale of these securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under
the securities laws of any such jurisdiction.
About Momenta:
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing
in the detailed structural analysis and design of complex sugars for
the development of improved versions of existing drugs, the development
of novel drugs and the discovery of new biological processes. Momenta
is also utilizing its ability to sequence sugars to create technology-enabled
generic versions of sugar-based and biologic drug products. The Company’s
most advanced product candidate is M-Enoxaparin, a technology-enabled
generic version of Lovenox®. Based on its understanding of complex
sugars, Momenta has created a diversified pipeline of near-term product
opportunities, novel development products and discovery candidates.
Momenta was founded in 2001 and is headquartered in Cambridge, MA.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does not form
a part of this press release.
Contact:
Michael A. Lawless
Momenta Pharmaceuticals, Inc.
617-395-5189
|
